Advertisement
Anindya Chatterjee will work closely with AOBO's management team to shapeand execute the Company's core growth initiatives, including acquisition-ledexpansion and capital markets strategy. Further, he will also serve as theCompany's interface with the investment community, playing a crucial role inenhancing investor communications and transparency.
Advertisement
Anindya Chatterjee brings more than thirteen years of capital marketsexperience to AOBO. He was previously a Managing Director in equity researchat Jefferies & Co, where he headed Emerging Asian (China & India) equityresearch. He was also a Strategist and Economist focused on Non-Japan Asiafor Bear Stearns & Company in Hong Kong. He held similar positions at IDEAINC. in New York, and NatWest Markets in Singapore, where he was the EmergingMarkets Strategist and Regional Economist and Equity Strategist, respectively.He also was the Head of Research at ANZ Investment Bank in India, and heldresearch positions at HSBC Securities and Smith New Court Securities.
Tony Liu, AOBO's Chief Executive Officer and Chairman stated, "We areexcited to add Anindya to our core management team at this crucial time ofrapid business expansion. Anindya brings a deep understanding our Company,our sector and our corporate culture in addition to his invaluable capitalmarkets experience, and long-standing credibility among global institutionalinvestors."
Anindya Chatterjee stated, "As an equity analyst, I have interactedregularly with AOBO's investors and management team, and I am very pleased toaccept this strategic role at a Company with such strong fundamentalperformance, exciting growth prospects, and cohesive team. With my investmentresearch experience and knowledge of the capital markets, I look forward toenhancing and executing AOBO's key growth initiatives, including theacquisition strategy and navigating the U.S. capital markets."
About American Oriental Bioengineering Inc.
American Oriental Bioengineering Inc. is a pharmaceutical companydedicated to improving health through the development, manufacture andcommercialization of a broad range of prescription and over the counterproducts in China. For more information, visit http://www.bioaobo.com.
Statements made in this press release are forward-looking and are madepursuant to the safe harbor provisions of the Securities Litigation Reform Actof 1995. Such statements involve risks and uncertainties that may causeactual results to differ materially from those set forth in these statements.The economic, competitive, governmental, technological and other factorsidentified in the Company's filings with the Securities and ExchangeCommission, including the Form 10-K for the year ended December 31, 2007, maycause actual results or events to differ materially from those described inthe forward looking statements in this press release. The Company undertakesno obligation to publicly update or revise any forward-looking statements,whether because of new information, future events, or otherwise.
SOURCE American Oriental Bioengineering, Inc.
